Getting Mounjaro Without a Subscription: The Facts

What the evidence says about long-term Mounjaro treatment

NICE's appraisal of tirzepatide, published in December 2024 and updated in September 2025, draws on the SURMOUNT-1 trial (2,539 adults with obesity, followed for 72 weeks) which reported average body-weight reductions of around 20–21% at the 15 mg dose. The NICE tirzepatide guidance (TA1026) also specifies that if a patient hasn't achieved at least 5% weight loss after six months at their highest tolerated dose, continuing treatment should be reviewed. That built-in checkpoint matters here: it is part of why responsible prescribers re-assess before every repeat, rather than dispatching the next pen automatically. Treatment that bypasses regular review isn't just commercially questionable, it runs counter to the clinical framework the medicine was approved within.

The titration schedule itself reinforces this. Mounjaro starts at 2.5 mg and moves through 5, 7.5, 10, 12.5 and 15 mg, with the prescriber deciding when each step is appropriate. Dose changes need clinical sign-off, which is another reason that thoughtful services build review into every repeat rather than streamlining it away.

Why some providers push subscriptions, and what to watch for

Subscription models are common in direct-to-consumer health services because they smooth revenue and reduce drop-off. For the patient, the risk is auto-renewal without adequate review: a pen arrives because the calendar said so, not because a prescriber checked your latest weight, symptoms and any new medicines. If you're looking at how Mounjaro subscription services work, it's worth reading exactly what happens at renewal: does a clinician actually review your case, or does the prescription roll over?

Red flags include services that don't ask for weight evidence before each repeat, can't tell you who your prescriber is, or bury auto-renewal terms in fine print. You can verify any online pharmacy on the GPhC register, a few seconds there is worth more than any marketing promise. For broader context on what legitimate private Mounjaro supply involves, the clinical assessment requirements are worth understanding before you commit to any provider.

The cost picture for subscription-free supply

One practical concern people have is whether avoiding a subscription means paying more per pen. Not necessarily. Subscriptions sometimes offer a marginal per-unit discount in exchange for commitment, but Eli Lilly raised Mounjaro's UK list price from around £122 to around £330 per four-week pen at the highest dose from 1 September 2025, and typical private prices since then range roughly £149–£375 a month depending on dose and provider. More detail on the Lilly price increase and what it means for private patients helps explain why some of the very cheap listings you'll see online no longer reflect what legitimate supply costs.

We know it can feel dispiriting to see that price range. That's a fair reaction. The value question, though, is less about subscription versus single-order and more about what's actually included: at nume, the consultation, prescription, clinical re-review and next-working-day tracked delivery are all covered in one transparent price, no add-ons, no surprises at checkout. Treatment pricing is shown on our treatment page; we don't publish per-pen prices here because they vary by dose.

Who can access Mounjaro without a subscription through a regulated service

The eligibility criteria don't change based on whether you use a subscription model. The Mounjaro SmPC (available on the Electronic Medicines Compendium) licenses the medicine for adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone doesn't determine approval: a prescriber looks at the full picture, including any contraindications, current medicines and relevant medical history.

Mounjaro is not licensed for use during pregnancy, breastfeeding, or when actively trying to conceive, and it isn't suitable for under-18s. People with a history of medullary thyroid carcinoma or certain gastrointestinal conditions will need to discuss their options with a prescriber. If you're on treatment and have noticed changes to your cycle, it's worth reading about whether Mounjaro can cause irregular periods before raising it with your prescriber. Our tirzepatide overview covers the mechanism and clinical background if you want the fuller picture first.